Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Connect Biopharma Holdings Ltd
Retained Earnings
Connect Biopharma Holdings Ltd
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
Retained Earnings
-¥345.4m
|
CAGR 3-Years
52%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Retained Earnings
-¥62.7B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Retained Earnings
¥19.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Retained Earnings
-¥3.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Retained Earnings
¥9.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Retained Earnings
¥2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Connect Biopharma Holdings Ltd
Glance View
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
See Also
What is Connect Biopharma Holdings Ltd's Retained Earnings?
Retained Earnings
-345.4m
CNY
Based on the financial report for Dec 31, 2025, Connect Biopharma Holdings Ltd's Retained Earnings amounts to -345.4m CNY.
What is Connect Biopharma Holdings Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
20%
Over the last year, the Retained Earnings growth was 0%. The average annual Retained Earnings growth rates for Connect Biopharma Holdings Ltd have been 52% over the past three years , 20% over the past five years .
